Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175264 | 0.87 | KMT2A (0.51) | DBHLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2175946 | 0.84 | LMNA (0.46) | DBHLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18860559 | 0.84 | MEN1 (0.46) | DBHLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2174190 | 0.83 | POLB (0.57) | DBHLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2177202 | 0.82 | MAPK14 (0.53) | — | |
| SCHEMBL2175721 | 0.80 | MEN1 (0.52) | LMNAMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL2177234 | 0.79 | MAPK14 (0.44) | LMNASMN1; SMN2TSHR | |
| SCHEMBL2178944 | 0.78 | MEN1 (0.45) | MEN1KMT2ATSHR | |
| SCHEMBL2175595 | 0.78 | MAPK14 (0.43) | LMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2175674 | 0.77 | MAPK14 (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | DBH 3923/4885LMNA 1691/4885MEN1 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.